IAS 2013: End-Stage Kidney Disease Is More Common Among People with HIV
- Details
- Category: Liver & Kidney Disease
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
HIV positive people in the U.S. and Canada are nearly 4 times as likely to develop end-stage renal disease than HIV negative people in the general population, largely driven by a very high rate among blacks, researchers reported last month at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: People with HBV or HCV Coinfection May Not Respond as Well to HIV Treatment
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
HIV positive people with hepatitis B or C coinfection in Asia had lower CD4 T-cell counts, saw smaller CD4 cell gains after starting antiretroviral therapy, and had a higher risk of death, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: Raltegravir/Etravirine Dual Regimen Maintains Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
A regimen of raltegravir (Isentress) plus etravirine (Intelence) without NRTIs or protease inhibitors was able to keep HIV in check after switching from a standard regimen if patients did not have pre-existing NNRTI resistance, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
IAS 2013: Life Expectancy of HIV+ People in North America Increased by 15 Years
- Details
- Category: HIV Treatment
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
A 20-year-old HIV positive person on effective antiretroviral therapy (ART) in the U.S. or Canada has a remaining life expectancy of about 50 years, approaching that of HIV negative individuals, according to a poster presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last month in Kuala Lumpur.
IAS 2013: Single Tablet Regimens Do Not Always Produce Better HIV Treatment Outcomes
- Details
- Category: HIV Treatment
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
One pill per day does not necessarily lead to more durable HIV suppression than regimens containing more pills taken twice-daily, according to a study presented at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
More Articles...
- IAS 2013: Combination Prevention Trial Shows Drop in HIV Incidence, Increase in Testing
- IAS 2013: Acute Retroviral Syndrome Linked to HIV Disease Progression
- IAS 2013: Middle-income Countries Outside Africa Pay Four Times More for Antiretroviral Drugs
- IAS 2013: Cost of HIV Drugs in Resource-limited Settings [VIDEO]
Web Design and Development by